Oncology

CGC Mutation Panels

Colorectal Cancer Screening (methylation analysis of SEPT9 gene) – NOT Avalible in North America
Drug metabolism (CYP2D6, CYP2C9, CYP2C19, CYP3A4 and NAT2 genes)
E-cadherin (sequence analysis)
EGFR (sequence analysis)
Familial Adenomatous Polyposis (APC gene)
Familial Breast/Ovarian Cancer (deletion/duplication analysis of BRCA1 and BRCA2 genes)
Familial Breast/Ovarian Cancer (sequence analysis of BRCA1 and BRCA2 genes)
Gastric cancer (KRAS gene)
Hepatic Adenoma (HNF1A gene)
Hereditary Non-polyposis Colorectal Cancer, type 1 and 2, HNPCC (deletion/duplication analysis of MLH1 and MSH2 genes)
Hereditary Non-polyposis Colorectal Cancer, type 1 and 2, HNPCC (sequence analysis of MLH1 and MSH2 genes)
Hereditary Pancreatic Cancer (KRAS gene)
Li-Fraumeni Syndrome (TP53 gene)
Lung Cancer (tumor tissue,paraffin sections on EGFR3 gene)
Microsatellite Instability in Colorectal Cancer
Neurofibromatosis type I (deletion/duplication analysis of NF1 gene)
Neurofibromatosis type I (NF1 gene)
Neurofibromatosis type II (NF2 gene)
Resistance to Imatinib (c-KIT)
Resistance to Methotrexate (MTHFR)
Resistance to Methotrexate (SLC19A1) (under development)
Susceptibility to Cetuximab (KRAS)
Susceptibility to Irinotecan (UGT1A1)
Tamoxifen pharmacogenetics
TP53 (sequence analysis)
Von Hippel-Lindau Syndrome (deletions/duplications and mutations on VHL gene)
Xenobiotics metabolism (GSTM1, GSTT1 and NAT2 genes)
Thrombophilia and Warfarin Pharmacogenetics See CGC Mutation Panel